ArticleDiscover oncology2026
Multi-omics analysis reveals TM4SF19 as a diagnostic and prognostic biomarker in bladder cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveBladder cancer poses a significant clinical challenge due to its high recurrence and heterogeneity, necessitating novel biomarkers. To explore the multidimensional role of TM4SF19, a tetraspanin family member, as a potential diagnostic and prognostic biomarker in bladder cancer (BLCA) through multi-omics analysis.
methodsThis study integrated multi-omics data from public databases (TCGA, GEPIA, cBioPortal, TIMER, LinkedOmics) to analyze TM4SF19 expression, genomic alterations, prognostic significance, immune infiltration associations, and drug sensitivity in bladder cancer. Analytical methods included differential expression analysis (limma package), survival analysis (Kaplan-Meier and Cox regression), nomogram construction, functional enrichment (GSEA, KEGG), immune microenvironment assessment (MCPcounter, TIMER), and drug sensitivity evaluation (GDSC database). Statistical analyses were performed using R software (v4.0.2) with significance set at p < 0.05
resultsTM4SF19 was significantly upregulated in bladder cancer tissues (p < 0.01) and demonstrated high diagnostic accuracy (AUC = 0.831). High TM4SF19 expression correlated with advanced pathological stage, lymphovascular invasion, and poorer overall survival (p < 0.05). Functional analysis linked TM4SF19 to PI3K-Akt/MAPK signaling pathways and immune modulation, showing negative correlations with CD8⁺ T cells and B cell infiltration. TM4SF19 expression also negatively correlated with sensitivity to Trametinib and Docetaxel but positively with Navitoclax and AR-42, indicating its role in chemotherapy resistance.
conclusionTM4SF19 is a promising diagnostic and independent prognostic biomarker in BLCA, influencing tumor progression through signaling pathways and immune microenvironment modulation. Its association with chemotherapy resistance highlights its potential as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.